{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:51:04Z","timestamp":1790214664596,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eclinm.2026.103867","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:49:36Z","timestamp":1776080976000},"page":"103867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study"],"prefix":"10.1016","volume":"94","author":[{"given":"Megan A.","family":"Waldrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Bernardo","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah A.","family":"Camarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Branic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa","family":"Mehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja","family":"Ili\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103867_bib1","series-title":"GeneReviews\u00ae","article-title":"Spinal muscular atrophy","author":"Prior","year":"2024"},{"key":"10.1016\/j.eclinm.2026.103867_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103867_bib3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103867_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn careening: a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103867_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103867_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"19","key":"10.1016\/j.eclinm.2026.103867_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914873","article-title":"Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies","volume":"24","author":"Angilletta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.103867_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103867_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"15","key":"10.1016\/j.eclinm.2026.103867_bib10","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103867_bib11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.eclinm.2026.103867_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105313","article-title":"Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies","volume":"49","author":"Finnegan","year":"2025","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103867_bib16","first-page":"28","article-title":"What did we learn from new treatments in SMA? A narrative review","volume":"44","author":"Mercuri","year":"2025","journal-title":"Acta Myol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103867_bib17","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"issue":"18","key":"10.1016\/j.eclinm.2026.103867_bib18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103867_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.eclinm.2026.103867_bib22","first-page":"86","article-title":"WHO Motor Development Study: windows of achievement for six gross motor development milestones","volume":"450","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.eclinm.2026.103867_bib23","series-title":"Bayley Scales of Infant and Toddler Development: Administration Manual","author":"Bayley","year":"2006"},{"key":"10.1016\/j.eclinm.2026.103867_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1366943","article-title":"Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies","volume":"12","author":"Lagae","year":"2024","journal-title":"Front Pediatr"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103867_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/children9081207","article-title":"Changes in ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies","volume":"9","author":"Panagiotou","year":"2022","journal-title":"Children"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103867_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103867_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D'Silva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103867_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0883073820928784","article-title":"Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec","volume":"35","author":"Matesanz","year":"2020","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103867_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-024-05886-9","article-title":"Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study","volume":"184","author":"Lavie","year":"2024","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103867_bib30","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213799","article-title":"Gestational age at birth and clinical manifestations of spinal muscular atrophy","volume":"105","author":"Farrar","year":"2025","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103867_bib31","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103867_bib32","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103867_bib33","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103867_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.eclinm.2026.103867_bib35","article-title":"Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing \u226417 kg and \u226424 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study","volume":"49","author":"Saute","year":"2025","journal-title":"Lancet Reg Health, Am"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103867_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103867_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"issue":"2\u20133","key":"10.1016\/j.eclinm.2026.103867_bib38","first-page":"82","article-title":"Zolgensma\u00ae and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report","volume":"42","author":"Bitetti","year":"2023","journal-title":"Acta Myol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103867_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00431-025-06386-0","article-title":"Combination therapies in spinal muscular atrophy: a systematic review","volume":"184","author":"Bemanalizadeh","year":"2025","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.eclinm.2026.103867_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105454","article-title":"Real-world experience with switch to onasemnogene abeparvovec after initial therapy with nusinersen or risdiplam","volume":"55","author":"Chro\u015bci\u0144ska-Krawczyk","year":"2025","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103867_bib41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12883-025-04276-4","article-title":"Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series","volume":"25","author":"Svoboda","year":"2025","journal-title":"BMC Neurol"},{"issue":"23","key":"10.1016\/j.eclinm.2026.103867_bib42","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I","volume":"10","author":"Mirea","year":"2021","journal-title":"J Clin Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:08:35Z","timestamp":1778904515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026001148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"alternative-id":["S2589537026001148"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103867","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103867"}}